Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

Abstract Introduction A combination of targeted anticancer drugs with cytotoxic therapy can potentially overcome multidrug resistance. The multi-target kinase inhibitor sorafenib demonstrates synergistic activity when combined with chemotherapeutics in preclinical models. This phase I trial aimed to...

Full description

Saved in:
Bibliographic Details
Main Authors: Daphne W. M. Voogd, Merel J. J. Lucassen, Ruud van der Noll, Sybrand W. J. Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, Alwin D. R. Huitema, Jan H. M. Schellens, Neeltje Steeghs
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Oncology and Therapy
Subjects:
Medical oncology
Phase I clinical trial
Targeted therapy
Protein kinase inhibitor
Online Access:https://doi.org/10.1007/s40487-025-00340-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40487-025-00340-8

Similar Items